San Diego, CA — April 28, 2026 — Paradigm Clinical Research announces the addition of four board-certified physicians to its network of Partner Principal Investigators: Dr. Robert C. Fox (Redding, CA), Dr. Isabelle Amigues (Wheat Ridge, CO), Dr. Salman Mehboob (San Diego, CA), and Dr. Basil M. Hantash (Modesto, CA).Each physician brings deep clinical expertise and experience within their respective specialties, including ophthalmology, rheumatology, cardiology, dermatology and regenerative medicine. Their addition strengthens Paradigm’s ability to support clinical trials across a broad range of therapeutic areas.Dr. Robert C. Fox, a board-certified ophthalmologist based in Redding, California, has more than two decades of experience in general and pediatric ophthalmology. He practices at Shasta Eye Medical Group and serves as Director of Ophthalmology and Director of Quality Control at Shasta Regional Medical Center.Dr. Isabelle Amigues, based in Wheat Ridge, Colorado, is double board-certified in rheumatology and internal medicine and is the founder and CEO of UnabridgedMD. Her work focuses on autoimmune and inflammatory conditions, with research spanning rheumatoid arthritis, interstitial lung disease, and precision medicine approaches.Dr. Salman Mehboob, a board-certified interventional cardiologist in San Diego, California, serves as medical director and founding partner at Coastal Cardiovascular Care. His clinical and research expertise includes coronary and peripheral artery disease, with experience in both interventional and imaging-based cardiology.Dr. Basil M. Hantash, based in Modesto, California, is a physician-scientist and dermatologist with more than 30 years of experience in regenerative medicine. His work spans early-stage discovery through clinical research and regulatory approval and has contributed to more than a dozen FDA-approved products across medical devices, diagnostics, and biologics.
“These physicians represent the type of clinical and scientific leadership that defines our Partner PI model,” said Kurt Mussina, CEO of Paradigm Clinical Research. “They are deeply embedded in their communities and bring relevant expertise that supports both study execution and patient access.”Paradigm’s Partner Principal Investigator model enables board-certified physicians to participate in clinical research while continuing to care for patients within their established practices. Supported by Paradigm’s centralized operations and infrastructure, investigators are able to focus on clinical oversight while contributing to the advancement of new therapies.The addition of Drs. Fox, Amigues, Mehboob, and Hantash reflects continued growth in Paradigm’s investigator network and its ability to support studies across ophthalmology, autoimmune disease, cardiovascular disease, and dermatology.About Paradigm Clinical ResearchParadigm Clinical Research is a clinical research site organization supporting phase I–IV programs across metabolic disease, dermatology, pulmonology, neurology and psychiatry, ophthalmology, and vaccines and infectious disease. Paradigm operates wholly owned clinical trial sites with centralized governance and infrastructure designed to minimize operational variability across sites, a common challenge in multi-site clinical trials. In collaboration with more than 40 board-certified principal investigators, the company delivers expertly conducted clinical studies and access to diverse and specialty patient populations for sponsors and CRO partners. Additional information about the company is available at www.paradigm-research.com.